person
Pierre-André J.
- Country
- France
- Department
- Centre d’Investigation Clinique
Research Overview
assignment
4
Clinical Trials ·
- Phase II Study Evaluating the Efficacy and Safety of Secukinumab versus Combination Therapy in Patients with Active Severe Takayasu Arteritis
- Evaluation of Rituximab-Based Combination, Tocilizumab, and Tofacitinib in Granulomatosis with Polyangiitis Patients Unresponsive to Standard Therapy
- OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 prospective, open-label study
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
19
Sites with multiple studies
Has run more than one trial at 19 of 56 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in treating granulomatosis with polyangiitis (GPA), with particular emphasis on managing cases that show inadequate response to conventional treatments.
- PR3-ANCA positive vasculitis
- Refractory granulomatosis
- ANCA-associated vasculitis
Therapeutic Innovations
Focus on developing novel therapeutic approaches using targeted biological therapies and exploring alternative treatment pathways for resistant cases.
- Rituximab combinations
- Obinutuzumab therapy
- Disease-modifying antirheumatic drugs
Treatment Optimization
Expertise in salvage therapy strategies and development of treatment protocols for patients who have failed standard care approaches.
- Corticosteroid reduction protocols
- Remission induction strategies
- Alternative therapeutic pathways
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.